At Mayo Clinic in Arizona, researchers just unveiled a potentially significant breakthrough: an experimental two-drug combination that coaxes advanced kidney cancer into retreat, even when the disease has already outsmarted standard treatment.
Clear cell renal cell carcinoma, or ccRCC, is the most common form of kidney cancer in adults, and it's a stubborn opponent. Many patients eventually watch their tumors develop resistance to cabozantinib, a targeted therapy that once held promise but loses its grip as cancer cells find alternative pathways to survive and grow. This is where the urgency lies—for patients whose disease has progressed despite prior treatment, options dwindle quickly. That's why Dr. Yousef Zakharia and his team at Mayo Clinic decided to test whether adding a next-generation drug called darlifarnib to the cabozantinib regimen might overcome that resistance by attacking the signaling pathways cancer uses to thrive.
The results, presented at the 2026 International Kidney Cancer Symposium: Europe in Paris, are worth noting. In a phase 1a/b study of 18 patients who had already received cabozantinib—with about half having endured at least three prior therapies—the combination delivered real responses. Seven of 16 evaluable patients experienced tumor shrinkage, translating to a 44% overall response rate. Even more striking, disease control (meaning either tumor stability or shrinkage) was achieved in 15 of those 16 patients, a 94% success rate.
These numbers matter because they suggest the combination is working in a population where alternatives are scarce. "For many patients, the benefit of cabozantinib can be temporary. Tumors may develop resistance and activate alternative pathways that allow the cancer to continue growing," Dr. Zakharia explains. By layering darlifarnib onto the standard treatment, researchers found a way to interrupt those workaround pathways before the cancer fully escapes.
The study itself was deliberately small—a first-in-human trial designed to test safety and signal efficacy rather than prove it conclusively. That's the appropriate caution for experimental work. Dr. Zakharia acknowledges this directly: "These findings require validation in a larger clinical trial to confirm the efficacy observed thus far; however, the early signal is intriguing." A multicenter, international trial is already underway to test the combination in a larger group of patients.
What makes this moment genuinely hopeful is not overconfidence but clarity of purpose. ccRCC accounts for most kidney cancer cases, and once a patient's disease progresses despite treatment, the path forward narrows. Every tool that works—even preliminarily, even in a small cohort—deserves investigation. Darlifarnib plus cabozantinib doesn't represent a cure, but it does represent momentum. It shows researchers can still find ways to outwit resistance, to hit cancer where it's trying to hide.
For patients enrolled in that next, larger trial, this early signal could mean extended time with family, more years of living beyond a difficult diagnosis. That's what these numbers ultimately represent: not just percentages and response rates, but the possibility that treatment resistance doesn't have to be the final word.